Olema Pharmaceuticals, Inc. (OLMA)
OLMA moved a median of -0.15% 30 minutes after news, and -0.04% by the close. How OLMA actually reacts to news — the realized, point-in-time move the market made, measured across 405 labeled events over the last three years with zero look-ahead.
OLMA’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.28% | 40% | 404 |
| 30-min | -0.15% | 48% | 405 |
| 60-min | -0.35% | 42% | 405 |
| to close | -0.04% | 50% | 402 |
| Middle 50% of OLMA reactions | -1.80% to +1.54% |
|---|---|
| Median reaction (30-min) | -0.15% |
| Measured reactions | 405 |
Half of all Olema Pharmaceuticals, Inc. news events land between -1.80% and +1.54% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How OLMA reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 23 | -0.48% | 48% | -0.41% |
| Rating reiterations | 64 | -0.15% | 41% | -0.81% |
| Price-target raises | 12 | -0.51% | 25% | +0.64% |
| Price-target cuts | 10 | -0.77% | 30% | +0.31% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how OLMA ranks against every other measured name →
That’s how OLMA usually reacts — get an email when it moves on news →Email me when OLMA moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to OLMA's baseline. Nothing else.
Recent OLMA events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Olema Pharmaceuticals, For: Oct 12 | SEC filing · Form 8-K | SEC EDGAR | -1.46% | -3.66% | |
| Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.84% | -0.36% | |
| Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -1.01% | -1.65% | |
| Olema Oncology to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.58% | +1.93% | |
| Form 8-K Olema Pharmaceuticals, For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | +0.19% | +1.45% | |
| Olema Oncology Appoints Jason O’Byrne as Chief Financial Officer | Press release | GlobeNewswire | +0.19% | +1.45% | |
| Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +1.14% | -2.03% | |
| Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +2.31% | +1.51% | |
| Form 8-K Olema Pharmaceuticals, For: Jun 17 | SEC filing · Form 8-K | SEC EDGAR | -1.13% | +5.29% | |
| Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.89% | -1.41% | |
| Form 8-K Olema Pharmaceuticals, For: May 26 | SEC filing · Form 8-K | SEC EDGAR | +0.36% | -1.53% | |
| Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer | Press release | GlobeNewswire | +0.36% | -1.53% | |
| Form 8-K Olema Pharmaceuticals, For: May 21 | SEC filing · Form 8-K | SEC EDGAR | +2.88% | -1.51% | |
| Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting | Press release | GlobeNewswire | +2.88% | -1.51% | |
| Olema Oncology to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +1.36% | +5.60% | |
| Form 10-Q Olema Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.14% | -3.92% | |
| Form 8-K Olema Pharmaceuticals, For: May 12 | SEC filing · Form 8-K | SEC EDGAR | -1.14% | -3.92% | |
| Olema Oncology Reports First Quarter 2026 Financial and Operating Results | Press release | GlobeNewswire | -1.14% | -3.92% | |
| Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.74% | -1.22% | |
| Form 8-K Olema Pharmaceuticals, For: Apr 27 | SEC filing · Form 8-K | SEC EDGAR | +0.70% | +2.81% | |
| Form 8-K Olema Pharmaceuticals, For: Apr 27 | SEC filing · Form 8-K | SEC EDGAR | -0.28% | +0.49% | |
| Form ARS Olema Pharmaceuticals, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.28% | +0.49% | |
| Form DEF 14A Olema Pharmaceuticals, For: Apr 29 | SEC filing · Form DEF | SEC EDGAR | -0.28% | +0.49% | |
| Form DEFA14A Olema Pharmaceuticals, | SEC filing · Form DEFA14A | SEC EDGAR | -0.28% | +0.49% | |
| Olema Oncology Appoints Prakash Raman, Ph.D., to Board of Directors | Press release | GlobeNewswire | -0.28% | +0.49% | |
| Olema Oncology to Present Initial Clinical Data for OP-3136 at the 2026 ASCO Annual Meeting | Press release | GlobeNewswire | +0.66% | -2.75% | |
| Olema Oncology Announces Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting | Press release | GlobeNewswire | -0.42% | -1.13% | |
| Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.40% | +0.73% | |
| Olema Oncology to Present Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting | Press release | GlobeNewswire | -2.45% | -4.99% | |
| Form 10-K Olema Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.86% | +9.93% | |
| Form 8-K Olema Pharmaceuticals, For: Mar 16 | SEC filing · Form 8-K | SEC EDGAR | +0.86% | +9.93% | |
| Form S-8 Olema Pharmaceuticals, | SEC filing · Form S-8 | SEC EDGAR | +0.86% | +9.93% | |
| Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results | Press release | GlobeNewswire | +0.86% | +9.93% | |
| Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.42% | +1.67% | |
| Olema Oncology to Present at the TD Cowen 46th Annual Health Care Conference | Press release | GlobeNewswire | -1.51% | +1.09% | |
| Olema Oncology to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.38% | -5.30% | |
| Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.76% | +0.50% | |
| Form 8-K Olema Pharmaceuticals, For: Jan 27 | SEC filing · Form 8-K | SEC EDGAR | +2.28% | +9.43% | |
| Olema Oncology Announces Departure of Chief Operating and Financial Officer | Press release | GlobeNewswire | +2.28% | +9.43% | |
| Form 8-K Olema Pharmaceuticals, For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | -0.25% | -1.20% | |
| Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.34% | +0.16% | |
| Olema Oncology to Present at 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | +0.18% | -0.71% | |
| Form S-3ASR Olema Pharmaceuticals, | SEC filing · Form S-3ASR | SEC EDGAR | +0.37% | +3.12% | |
| Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.37% | +0.37% | |
| Olema Oncology to Participate in 8th Annual Evercore Healthcare Conference | Press release | GlobeNewswire | -0.04% | +7.93% | |
| Olema Oncology Announces Closing of $218.5 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares | Press release | GlobeNewswire | +1.06% | +7.82% | |
| Form 8-K Olema Pharmaceuticals, For: Nov 19 | SEC filing · Form 8-K | SEC EDGAR | -1.97% | +7.26% | |
| Olema Oncology Announces Pricing of $190.0 Million Public Offering of Common Stock | Press release | GlobeNewswire | -0.63% | -2.02% | |
| Form 8-K Olema Pharmaceuticals, For: Nov 18 | SEC filing · Form 8-K | SEC EDGAR | -0.63% | -2.02% | |
| Form S-3MEF Olema Pharmaceuticals, | SEC filing · Form S-3MEF | SEC EDGAR | -0.63% | -2.02% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the OLMA section they belong to.
Where else OLMA is measured.
OLMA earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Olema Pharmaceuticals, Inc.'s median reaction calculated?
Every labeled OLMA news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 405 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 48% of OLMA's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does OLMA's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.